Insulin sensitivity is preserved in mice made obese by feeding a high starch diet.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: eLife Sciences Publications, Ltd Country of Publication: England NLM ID: 101579614 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-084X (Electronic) Linking ISSN: 2050084X NLM ISO Abbreviation: Elife Subsets: MEDLINE
    • Publication Information:
      Original Publication: Cambridge, UK : eLife Sciences Publications, Ltd., 2012-
    • Subject Terms:
      Insulin Resistance* ; Glucose Intolerance* ; Diabetes Mellitus, Type 2*; Mice ; Animals ; Starch ; Obesity ; Diet, High-Fat/adverse effects ; Insulin ; Mice, Obese ; Ceramides ; Glucose
    • Abstract:
      Obesity is generally associated with insulin resistance in liver and muscle and increased risk of developing type 2 diabetes, however there is a population of obese people that remain insulin sensitive. Similarly, recent work suggests that mice fed high carbohydrate diets can become obese without apparent glucose intolerance. To investigate this phenomenon further, we fed mice either a high fat (Hi-F) or high starch (Hi-ST) diet and measured adiposity, glucose tolerance, insulin sensitivity, and tissue lipids compared to control mice fed a standard laboratory chow. Both Hi-ST and Hi-F mice accumulated a similar amount of fat and tissue triglyceride compared to chow-fed mice. However, while Hi-F diet mice developed glucose intolerance as well as liver and muscle insulin resistance (assessed via euglycaemic/hyperinsulinaemic clamp), obese Hi-ST mice maintained glucose tolerance and insulin action similar to lean, chow-fed controls. This preservation of insulin action despite obesity in Hi-ST mice was associated with differences in de novo lipogenesis and levels of C22:0 ceramide in liver and C18:0 ceramide in muscle. This indicates that dietary manipulation can influence insulin action independently of the level of adiposity and that the presence of specific ceramide species correlates with these differences.
      Competing Interests: AB, LS, TN, ES, HG, CY, SH, TP, SS, LP, MK, BY, LQ, GK, CB, NT, GC No competing interests declared
      (© 2022, Brandon, Small et al.)
    • References:
      J Physiol Biochem. 2021 Feb;77(1):175-189. (PMID: 33704694)
      Science. 1996 Nov 22;274(5291):1377-9. (PMID: 8910278)
      Cell Rep. 2019 Jan 2;26(1):1-10.e7. (PMID: 30605666)
      Nat Commun. 2018 Aug 21;9(1):3165. (PMID: 30131496)
      Mol Metab. 2021 Nov;53:101281. (PMID: 34175474)
      Diabetes Care. 2010 Nov;33(11):2477-83. (PMID: 20693348)
      Mol Metab. 2019 Jul;25:107-118. (PMID: 31029696)
      Biochem J. 1989 May 1;259(3):651-7. (PMID: 2499313)
      Front Endocrinol (Lausanne). 2021 Sep 06;12:706978. (PMID: 34552557)
      Obes Res. 2003 Nov;11(11):1295-305. (PMID: 14627749)
      Biochim Biophys Acta. 2015 Feb;1851(2):210-9. (PMID: 25490466)
      Lancet. 1998 Jul 25;352(9124):289. (PMID: 9690416)
      Trends Endocrinol Metab. 2012 Mar;23(3):116-24. (PMID: 22284531)
      Neurobiol Aging. 2015 Apr;36(4):1659-1669. (PMID: 25676385)
      Cell Metab. 2017 Aug 1;26(2):292-300. (PMID: 28768170)
      J Clin Med. 2019 Dec 12;8(12):. (PMID: 31842461)
      Obesity (Silver Spring). 2016 Apr;24(4):908-16. (PMID: 26916476)
      J Endocrinol. 2016 Mar;228(3):127-34. (PMID: 26668208)
      J Lipid Res. 2013 Dec;54(12):3322-33. (PMID: 24078708)
      Am J Physiol. 1999 Mar;276(3):R665-72. (PMID: 10070126)
      Nat Metab. 2019 Nov;1(11):1051-1058. (PMID: 32694860)
      Am J Physiol Endocrinol Metab. 2014 Dec 15;307(12):E1117-24. (PMID: 25352435)
      Biochim Biophys Acta. 2016 Nov;1861(11):1828-1839. (PMID: 27591968)
      Diabetes. 2017 Aug;66(8):2082-2091. (PMID: 28483801)
      J Clin Invest. 2007 Sep;117(9):2621-37. (PMID: 17717599)
      Endocrinology. 2010 Sep;151(9):4187-96. (PMID: 20660065)
      Diabetologia. 2016 Apr;59(4):785-98. (PMID: 26739815)
      Cells. 2022 Jan 08;11(2):. (PMID: 35053322)
      J Biol Chem. 2018 Apr 13;293(15):5731-5745. (PMID: 29440390)
      J Biol Chem. 2017 Nov 24;292(47):19135-19145. (PMID: 28982973)
      JCI Insight. 2018 Feb 8;3(3):. (PMID: 29415895)
      Am J Physiol Endocrinol Metab. 2009 Jul;297(1):E67-75. (PMID: 19366875)
      BMJ Open Diabetes Res Care. 2017 Jul 19;5(1):e000415. (PMID: 28878939)
      Physiol Behav. 2020 Mar 1;215:112773. (PMID: 31837387)
      Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):9597-602. (PMID: 24979806)
      Cell Metab. 2014 Mar 4;19(3):418-30. (PMID: 24606899)
      Diabetologia. 2013 May;56(5):1129-39. (PMID: 23423668)
      Cell Metab. 2019 Jan 8;29(1):183-191.e7. (PMID: 30318338)
      Mol Metab. 2019 Mar;21:36-50. (PMID: 30655217)
      Diabetologia. 2013 Jul;56(7):1638-48. (PMID: 23620060)
      J Clin Invest. 2019 Oct 1;129(10):3978-3989. (PMID: 31524630)
      Nutr Metab Cardiovasc Dis. 2021 Sep 22;31(10):2779-2791. (PMID: 34340900)
      Am J Physiol Endocrinol Metab. 2018 Mar 1;314(3):E251-E265. (PMID: 29118016)
      PLoS One. 2015 Mar 23;10(3):e0121959. (PMID: 25798922)
      Diabetes. 2007 Aug;56(8):2085-92. (PMID: 17519422)
      Annu Rev Biochem. 2006;75:367-401. (PMID: 16756496)
      Hepatology. 2014 Feb;59(2):713-23. (PMID: 23929732)
    • Contributed Indexing:
      Keywords: cell biology; ceramide; insulin sensitivity; mouse; obesity
    • Accession Number:
      9005-25-8 (Starch)
      0 (Insulin)
      0 (Ceramides)
      IY9XDZ35W2 (Glucose)
    • Publication Date:
      Date Created: 20221117 Date Completed: 20221202 Latest Revision: 20221208
    • Publication Date:
      20221213
    • Accession Number:
      PMC9711519
    • Accession Number:
      10.7554/eLife.79250
    • Accession Number:
      36394259